REVOLUTION AI ICU trial reshapes Australian critical care
REVOLUTION AI ICU trial reshapes Australian critical care
Why it matters
Adoption of AI guided oxygen protocols will become standard in Australian ICUs if the trial confirms safety and effectiveness. Hospitals will push to integrate validated tools, but data governance and cross border sharing remain concrete hurdles that operators must address.
REVOLUTION trial tests AI-guided oxygen delivery for patients on life support in ICUs across Australia and New Zealand in major centres.
ICU AI trial
The trial will recruit more than 24,000 patients across 50 ICUs with NZ Health Research Council funding a 5 million program grant and NHMRC backing the Australian arm. If validated, adoption of AI-guided oxygen protocols will become standard across Australian ICUs. Hospitals will push to integrate validated tools, but data governance and cross-border sharing are concrete hurdles that operators must address.
Billing shifts
From July 1 eligible patients may consent to bulk bill future appointments under an enduring assignment of benefit, covering MyMedicare registrants, aged care residents and Aboriginal community controlled organisations. The declaration requires patient name, signature, date and service details, plus how post service notifications will be delivered. Clinics will need to update billing workflows and notification systems. The policy is backed by ACT bulk-billing funding of 9.8 million until mid-2028 to recruit GP staff. Winners are vulnerable patients who gain predictable access, losers are clinics bearing more admin load and those outside endorsed prescriber networks.
Interoperable referrals
Grampians Health's HealthLink eReferral replaces fax with a digital path, connecting 40 practices to exchange more than 450 referrals to date. The system auto populates demographics, medical history and alerts and links with multiple GP systems, speeding care coordination. The gain goes to Grampians Health and its affiliated clinics, while the challenge is scaling governance and data security as the network expands across Victoria.
Adrenaline access
Neffy will join the PBS from 1 July, offering a needle-free nasal adrenaline option for patients at risk of anaphylaxis. The subsidy makes access cheaper and easier for families and prescribers, potentially reducing hospital visits, but it also adds pressure on the PBS budget if uptake rises.
Methodology: This digest condenses the source coverage listed below for faster scanning by Australian health teams. It is not medical advice.